IP Library Granted Patent US 9,801,866
Granted Patent B2
US 9,801,866 · App. 15/269,233 · Granted Oct 31, 2017

Fumarate analogs and uses thereof

Inventors: Matthew Duncton (San Bruno, CA); Somasekhar Bhamidipati (Foster City, CA); Jiaxin Yu (Foster City, CA); Ihab Darwish (San Carlos, CA); Rajinder Singh (Belmont, CA)
Assignee: Rigl Pharmaceutical, Inc.
A61K31/4439A61K31/41C07D257/04C07D401/04C07D403/12C07D405/04C07D405/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,801,866
App. No.
15/269,233
Granted
Oct 31, 2017
Kind
B2
Abstract

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Claims (64)

1. A method of treating a disease or disorder in a subject in need thereof, the method comprising:

administering to the subject a pharmaceutically effective amount of a compound of formula (A):

wherein either:

Y 1 is X a and Y 2 is hydrogen, or Y 2 is X a and Y 1 is hydrogen;

wherein X a is selected from carboxylic acid, carboxyl ester, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; and

R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (A);

or a salt or stereoisomer thereof,

wherein the administering is sufficient to treat the disease or disorder, and

wherein the disease or disorder is psoriasis or multiple sclerosis.

2. The method of claim 1 , wherein the compound is of formula (Ia) or (Ib):

wherein R 15 comprises a linking group and a compound of formula (Ia) or (Ib).

3. The method of claim 1 , wherein X a is a substituted heterocyclyl or a substituted heteroaryl, wherein the substituent on X a is X 1 , wherein X 1 is C 1-6 alkyl or a progroup.

4. The method of claim 1 , wherein the compound is a compound of formula (IIa) or (IIb):

wherein

R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (IIa) or (IIb); and

X 1 is hydrogen, C 1-6 alkyl or a progroup;

or a salt or stereoisomer thereof.

5. The method of claim 4 , wherein R 1 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

6. The method of claim 4 , wherein R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl.

7. The method of claim 6 , wherein R 1 is hydrogen, methyl, ethyl, isopropyl, cyclopentyl, 4-tetrahydropyranyl, —CH 2 CH 2 OCH 3 , —CH 2 OCH 3 , —CH 2 C(O)OCH 3 , or —CH 2 CH(CH 3 ) 2 OH.

8. The method of claim 3 , wherein X 1 is C 1-6 alkyl.

9. The method of claim 7 , wherein X 1 is methyl or tert-butyl.

10. The method of claim 3 , wherein X 1 is a progroup of the formula:

wherein

L 1 is a linking group;

X 2 is optional and selected from O, N and S;

R 2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, aminoacyl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and

R 3 and R 4 are each independently optional and selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, oxo, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or

R 2 together with X 2 and either R 3 or R 4 form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl.

11. The method of claim 10 , wherein X 1 is selected from:

wherein

L 1 is a C 1-6 alkyl or substituted C 1-6 alkyl;

R 5 and R 6 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or

R 5 and R 6 together with the nitrogen to which they are attached form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl; and

R 7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and —OR 14 where R 14 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

12. The method of claim 11 , wherein X 1 is selected from:

wherein

R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen, alkyl and substituted alkyl.

13. The method of claim 12 , wherein R 8 and R 9 are each independently selected from hydrogen and C 1-6 alkyl.

14. The method of claim 13 , wherein R 8 and R 9 are each hydrogen.

15. The method of claim 13 , wherein R 8 is hydrogen and R 9 is C 1-6 alkyl.

16. The method of claim 12 , wherein R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen and C 1-6 alkyl.

17. The method of claim 16 , wherein R 10 , R 11 , R 12 and R 13 are each hydrogen.

18. The method of claim 16 , wherein one of R 10 , R 11 , R 12 and R 13 is methyl and the remaining are hydrogen.

19. The method of claim 16 , wherein two of R 10 , R 11 , R 12 and R 13 are methyl and the remaining are hydrogen.

20. The method of claim 1 , wherein the linking group is —(CH 2 ) n —Z y —(CH 2 ) m —,

wherein

n is an integer from 1 to 6;

m is 0 or an integer from 1 to 6;

y is 0 or 1; and

Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—.

21. The method of claim 20 , wherein the compound has one of the following formulae:

wherein

X 1a and X 1b are each independently selected from C 1-6 alkyl and a progroup; and

Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—.

22. The method of claim 1 , wherein R 1 is:

wherein X 1b is selected from C 1-6 alkyl and a progroup.

23. The method of claim 22 , wherein the compound has one of the following formulae:

wherein X 1 and X 1b are each independently selected from C 1-6 alkyl and a progroup.

24. The method of claim 23 , wherein X 1 and X 1b are each independently a C 1-6 alkyl.

25. The method of claim 24 , wherein the compound has the structure:

26. The method of claim 1 , wherein the compound is selected from:

27. The method of claim 1 , wherein the compound is selected from:

wherein X 1 is a progroup.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2016
From: DUNCTON, MATTHEW; BHAMIDIPATI, SOMASEKHAR; YU, JIAXIN; DARWISH, IHAB; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 040394/0993 →
Continuity (3)
Continuation 14815589 · Jul 31, 2015
Provisional Application 62033023 · Aug 4, 2014
Related Publication 20170065569A1 · Mar 9, 2017